Jardiance Cost in West Virginia 2026: Cash Price, Medicaid, Compounding, and Savings Options

What Is the Cash Price of Jardiance in West Virginia in 2026?

Retail pharmacies in West Virginia price Jardiance at roughly $680 per month for a 30-tablet supply in 2026, which matches the Boehringer Ingelheim and Eli Lilly manufacturer list price. Without insurance or a savings program, that figure climbs to more than $8,100 per year. GoodRx and similar coupon platforms sometimes bring the price down to $620 to $650 at specific pharmacies, though this varies by zip code and pharmacy contract.

The list price has increased by approximately 4 to 6 percent annually since Jardiance launched in the United States in 2014. Jardiance received FDA approval for type 2 diabetes in August 2014, followed by a heart failure indication in 2021 and a chronic kidney disease indication in 2023. Each additional indication broadened the pool of patients who might benefit from the drug, which also expanded formulary negotiations.

West Virginia sits among the states with the highest rates of type 2 diabetes in the country. The CDC reports that 15.7 percent of West Virginia adults had diagnosed diabetes in 2022, compared to a national average of 11.6 percent. [1] That disease burden makes the $680 monthly price particularly consequential for patients here.

Empagliflozin's clinical value is well-documented. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death compared to placebo over a median 3.1-year follow-up. [2] That outcome data has made Jardiance a guideline-preferred agent in patients with type 2 diabetes and established cardiovascular disease, where cost barriers directly affect adherence.

Does West Virginia Medicaid Cover Jardiance?

West Virginia Medicaid does not cover Jardiance as of 2026. The state's preferred drug list (PDL) excludes empagliflozin across all its managed care organizations, which means Medicaid enrollees cannot access it without a non-preferred drug exception, and those exceptions are rarely approved for SGLT2 inhibitors when older agents are available on formulary.

This contrasts with federal Medicaid policy direction. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors for patients with type 2 diabetes and heart failure or chronic kidney disease regardless of HbA1c level, stating: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended." [3] West Virginia's PDL does not yet reflect this recommendation.

Medicaid enrollees who have heart failure with reduced ejection fraction may find some success with a prior authorization request citing the 2022 ACC/AHA heart failure guidelines, which give empagliflozin a Class I recommendation. That pathway is slow and uncertain. A prescriber who documents that a patient failed or cannot tolerate metformin and that an SGLT2 inhibitor is medically necessary has the best chance of approval, but there is no guarantee.

Patients on West Virginia Medicaid who cannot get coverage approved have two practical options: the manufacturer patient assistance program or a licensed compounding pharmacy.

Which Private Insurance Plans Cover Jardiance in West Virginia?

Commercial insurer coverage varies significantly. Most large employer-sponsored plans in West Virginia do cover Jardiance, though it typically sits on Tier 3 or Tier 4 of the formulary. Tier 3 copays in West Virginia range from $50 to $100 per month, and Tier 4 copays can reach $150 to $200 before the deductible is met.

Anthem Blue Cross Blue Shield of West Virginia covers Jardiance on its commercial formulary with a prior authorization requirement for the CKD indication in patients with eGFR below 45 mL/min/1.73 m2. The Medicare Part D situation is separate from commercial plans. Jardiance is covered by many Part D plans, and beginning in 2025, the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending has meaningfully reduced costs for West Virginia Medicare beneficiaries who were previously reaching catastrophic coverage thresholds.

West Virginia's State Health Benefit Plan, which covers state employees and teachers, lists empagliflozin on its preferred formulary for enrollees who have a documented diagnosis of heart failure, CKD, or type 2 diabetes with cardiovascular disease risk factors. Checking the 2026 plan formulary directly with your HR department is the most reliable way to confirm your specific tier and prior authorization requirements, as formularies change annually on January 1.

How Does the Boehringer Ingelheim and Lilly Savings Card Work in West Virginia?

The Jardiance Savings Card is available to commercially insured patients and, under a separate assistance program, to uninsured patients. Commercially insured West Virginia residents who are not enrolled in a government-funded program (Medicare, Medicaid, CHIP, TRICARE) may pay as little as $10 per month for Jardiance through the savings card. The card covers the gap between the insurance copay and $10, up to a defined monthly cap that the manufacturers periodically adjust.

Uninsured West Virginia patients may qualify for the Lilly Cares Foundation or Boehringer Ingelheim Cares patient assistance programs, which can provide Jardiance at no cost for qualifying low-income patients. Income eligibility thresholds generally sit at 400 percent of the federal poverty level, and the application requires proof of income and a prescription from a licensed provider.

To activate the savings card, patients can visit the Jardiance website or ask their pharmacist to process it. The card is not accepted at pharmacies that primarily serve Medicaid or Medicare patients, and it cannot be stacked with a GoodRx coupon at the same transaction. Using the card at a West Virginia pharmacy is straightforward: the pharmacist enters the group and member ID printed on the card, and the adjusted price appears at the point of sale.

Is Compounded Empagliflozin Legal in West Virginia?

Compounded empagliflozin is legal in West Virginia when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. West Virginia participates in the standard 503A framework established under the Drug Quality and Security Act of 2013, which permits compounding pharmacies to prepare non-commercially-available formulations for individual patients when there is a documented clinical need.

The FDA does not currently list empagliflozin as a commercially available drug shortage, and it does not appear on the FDA's 503A bulk drug substances list. This creates a gray area. Some compounding pharmacies argue that compounded empagliflozin formulations differ sufficiently from the commercial product to be permissible, while the FDA's enforcement posture has tightened on SGLT2 inhibitors since 2024. Patients and prescribers should confirm the regulatory status of their specific compounding pharmacy before proceeding.

A practical decision framework for West Virginia patients considering compounded empagliflozin:

1. Confirm that the 503A pharmacy is licensed in West Virginia and that the compounding pharmacist can provide a state board registration number.
2. Ask for a certificate of analysis (COA) for each batch, which verifies potency and purity testing by an independent laboratory.
3. Have your prescriber document the clinical rationale for compounding rather than using the brand product (typically cost or documented intolerance to an excipient).
4. Understand that compounded drugs are not FDA-approved and do not carry the same safety, efficacy, or quality guarantees as the brand product.

When sourced through a legitimate, licensed 503A pharmacy paired with a telehealth subscription service, compounded empagliflozin in West Virginia can cost between $0 and $99 per month, compared to $680 for the brand. That price differential is the primary driver of patient interest.

Can You Get a Jardiance Prescription via Telehealth in West Virginia?

Yes. West Virginia permits telehealth prescribing of Schedule III to V controlled substances under Ryan Haight Act exemptions, and non-controlled medications like empagliflozin face no additional telehealth restrictions. A licensed West Virginia physician, nurse practitioner, or physician assistant can prescribe Jardiance after a synchronous audio-video visit, which is the current telehealth standard in the state.

West Virginia adopted permanent telehealth parity legislation in 2021, meaning that commercial insurers must reimburse telehealth visits at the same rate as in-person visits for covered services. This makes telehealth a cost-effective access pathway for patients in rural West Virginia counties, where the nearest endocrinologist may be 60 to 90 minutes away.

Several HealthRX-affiliated providers are licensed in West Virginia and can evaluate patients for empagliflozin across its approved indications: type 2 diabetes, heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease with albuminuria. Patients will need to provide recent lab work, including HbA1c, eGFR, and urine albumin-to-creatinine ratio, to guide indication-appropriate prescribing.

The DAPA-HF trial (N=4,744) established the heart failure benefit for dapagliflozin, a related SGLT2 inhibitor, and the EMPEROR-Reduced trial (N=3,730) replicated that finding for empagliflozin specifically, showing a 25% relative risk reduction in the composite of cardiovascular death or worsening heart failure. [4] These trial results underpin the 2022 ACC/AHA guideline recommendation and give prescribers a strong clinical basis for initiating therapy via telehealth without requiring an in-person cardiology visit.

What Is the Cheapest Way to Get Jardiance in West Virginia?

The cheapest path depends on your insurance status.

If you have commercial insurance, apply the Jardiance Savings Card first. Many commercially insured patients pay $10 per month. If your insurance does not cover Jardiance at all, or if you are uninsured, the Lilly Cares and Boehringer Ingelheim Cares patient assistance programs may provide the drug at no cost. Income documentation is required.

For patients who do not qualify for those programs and cannot afford $680 per month, compounded empagliflozin from a licensed 503A pharmacy is the lowest-cost option currently available in West Virginia, provided the patient and prescriber accept the regulatory considerations outlined above. Prices at reputable compounding pharmacies run $30 to $99 per month for a supply equivalent to 10 mg daily.

GoodRx discounts at major West Virginia retail pharmacies (Kroger, Walgreens, CVS, Walmart) range from $620 to $650, which saves $30 to $60 per month versus list price but does not come close to the savings card or compounding options.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently carry empagliflozin as of January 2026, though the platform has expanded rapidly and may list it by mid-year. Checking the site directly is worthwhile for patients who use it for other medications.

Patients on Medicare Part D should calculate their total out-of-pocket cost under the 2025 to 2026 $2,000 annual cap. For a patient who takes Jardiance as their only expensive drug, the monthly effective cost under Part D may be lower than the savings card, particularly after the first quarter of the plan year.

How Does Empagliflozin Work and Why Is It Prescribed?

Empagliflozin belongs to the SGLT2 inhibitor drug class. It blocks the sodium-glucose cotransporter 2 in the proximal tubule of the kidney, preventing reabsorption of approximately 70 grams of glucose per day and causing that glucose to be excreted in the urine. The result is a sustained reduction in blood glucose that does not depend on insulin secretion.

The drug's non-glycemic effects explain much of its cardioprotective and nephroprotective activity. By reducing sodium reabsorption alongside glucose, empagliflozin lowers intraglomerular pressure, reduces tubuloglomerular feedback, decreases blood pressure by 3 to 5 mmHg systolic, and produces a modest osmotic diuresis that reduces cardiac preload. These mechanisms operate independently of glucose lowering, which is why the drug shows benefit even in patients with eGFR values too low for meaningful HbA1c reduction.

The EMPA-REG OUTCOME trial enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Over a median follow-up of 3.1 years, empagliflozin reduced the rate of cardiovascular death by 38% (3.7% vs. 5.9%, P<0.001) and reduced hospitalization for heart failure by 35% versus placebo. [2] These are absolute risk reductions that translate directly into lives saved at the population level, which is why guidelines from the American Diabetes Association, the ACC, and the AHA now list SGLT2 inhibitors as preferred agents in high-risk patients.

The EMPEROR-Preserved trial (N=5,988) further showed that empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization in patients with HFpEF (ejection fraction above 40%), a condition for which very few therapies had previously shown benefit. [5] The relative risk reduction was 21% (P<0.001).

Typical dosing starts at 10 mg once daily taken in the morning, with or without food. The dose may be increased to 25 mg once daily for additional glycemic control in type 2 diabetes when tolerated. For heart failure and CKD indications, 10 mg once daily is used regardless of diabetes status.

Common adverse effects include genital mycotic infections (approximately 4% in women, 2% in men), urinary tract infections, and a small risk of diabetic ketoacidosis (DKA), which occurs even at normal blood glucose levels. Empagliflozin should be held 3 days before any major surgery, fasting state, or prolonged illness because of DKA risk. Patients should not use it if eGFR falls below 20 mL/min/1.73 m2.

West Virginia-Specific Prescribing Considerations

West Virginia has one of the highest rates of chronic kidney disease in the United States, driven by the combination of high diabetes prevalence, hypertension, and historically limited access to nephrology care in rural counties. The CKD indication for empagliflozin, based on the EMPA-KIDNEY trial (N=6,609), which showed a 37% relative risk reduction in kidney disease progression or cardiovascular death [6], makes this drug particularly relevant for West Virginia patients.

The EMPA-KIDNEY trial is notable because it enrolled patients with eGFR as low as 20 mL/min/1.73 m2, and the benefit was consistent regardless of whether patients had diabetes. Roughly 46% of EMPA-KIDNEY participants did not have type 2 diabetes, which expanded the labeled CKD indication to non-diabetic patients with proteinuria.

For West Virginia providers, the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guideline states: "We recommend treatment with an SGLT2 inhibitor for patients with type 2 diabetes, CKD, and eGFR >20 mL/min/1.73 m2." [7] This recommendation level (Grade 1A) is the strongest in the KDIGO system, and it provides a clear clinical basis for prescribing empagliflozin even when Medicaid coverage is denied.

West Virginia also has above-average rates of obesity. Empagliflozin produces modest weight loss of 2 to 3 kg on average, which is less than GLP-1 receptor agonists like semaglutide (14.9% body weight reduction in STEP-1, N=1,961 [8]) but meaningful for patients who cannot tolerate injectable therapy.

One West Virginia-specific logistical note: 503A compounding pharmacies licensed in other states can ship compounded empagliflozin to West Virginia patients, provided they hold a non-resident pharmacy permit from the West Virginia Board of Pharmacy. Patients should verify this permit before sending payment or transferring prescription information.